JP2009526833A - 代替療法を最適化し、薬局方を全体的な嗜癖の治療に拡大適用するための新規な薬剤組成物 - Google Patents

代替療法を最適化し、薬局方を全体的な嗜癖の治療に拡大適用するための新規な薬剤組成物 Download PDF

Info

Publication number
JP2009526833A
JP2009526833A JP2008554881A JP2008554881A JP2009526833A JP 2009526833 A JP2009526833 A JP 2009526833A JP 2008554881 A JP2008554881 A JP 2008554881A JP 2008554881 A JP2008554881 A JP 2008554881A JP 2009526833 A JP2009526833 A JP 2009526833A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
prodopaminergic
amisulpride
dose
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008554881A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009526833A5 (enExample
Inventor
サンチェス，マリオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trimaran Ltd
Original Assignee
Trimaran Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimaran Ltd filed Critical Trimaran Ltd
Publication of JP2009526833A publication Critical patent/JP2009526833A/ja
Publication of JP2009526833A5 publication Critical patent/JP2009526833A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2008554881A 2006-02-17 2007-02-19 代替療法を最適化し、薬局方を全体的な嗜癖の治療に拡大適用するための新規な薬剤組成物 Withdrawn JP2009526833A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/FR2006/000372 WO2007096489A1 (fr) 2006-02-17 2006-02-17 Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
PCT/IB2007/000390 WO2007093909A1 (fr) 2006-02-17 2007-02-19 Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement globla des addictions

Publications (2)

Publication Number Publication Date
JP2009526833A true JP2009526833A (ja) 2009-07-23
JP2009526833A5 JP2009526833A5 (enExample) 2010-04-08

Family

ID=37054597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008554881A Withdrawn JP2009526833A (ja) 2006-02-17 2007-02-19 代替療法を最適化し、薬局方を全体的な嗜癖の治療に拡大適用するための新規な薬剤組成物

Country Status (7)

Country Link
US (1) US20110039834A1 (enExample)
EP (2) EP1988883A1 (enExample)
JP (1) JP2009526833A (enExample)
CN (1) CN101420944A (enExample)
AU (1) AU2007216255A1 (enExample)
CA (1) CA2642561A1 (enExample)
WO (2) WO2007096489A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
JP6158810B2 (ja) * 2011-08-18 2017-07-05 バイオデリバリー サイエンシズ インターナショナル，インコーポレーテッド ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CA3175428A1 (en) * 2020-04-13 2021-10-21 aiberry, Inc. Multimodal analysis combining monitoring modalities to elicit cognitive states and perform screening for mental disorders
CN112245434A (zh) * 2020-11-09 2021-01-22 深圳善康医疗健康产业有限公司 一种纳曲酮和利培酮复方缓释组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
CZ296263B6 (cs) * 1996-03-25 2006-02-15 Eli Lilly And Company Farmaceutická kompozice pro lécení bolesti a jejípouzití
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CA2525366A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
EP1644335A4 (en) * 2003-07-11 2008-06-04 Bristol Myers Squibb Co TETRAHYDROQUINOLINE DERIVATIVES COMPRISING MODULATORS OF CANNABINOID RECEPTORS
US7326706B2 (en) * 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
EP1670460B1 (en) * 2003-10-10 2014-11-26 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
PT1697371E (pt) * 2003-12-19 2007-08-03 Bristol Myers Squibb Co Heterocíclos azabicíclicos como moduladores do receptor de canabinóides
US20050181071A1 (en) * 2004-02-18 2005-08-18 Binder Michael R. Method for the treatment of clinical depression
FR2877573B1 (fr) * 2004-11-05 2007-02-02 Debussy Holding Sa Nouvelles compositions pharmaceutiques et leurs utilisations pour lutter contre les differentes formes d'accoutumance aux drogues

Also Published As

Publication number Publication date
EP1988883A1 (fr) 2008-11-12
US20110039834A1 (en) 2011-02-17
AU2007216255A1 (en) 2007-08-23
WO2007096489A1 (fr) 2007-08-30
CN101420944A (zh) 2009-04-29
EP2015739A1 (fr) 2009-01-21
WO2007093909A1 (fr) 2007-08-23
CA2642561A1 (fr) 2007-08-23

Similar Documents

Publication Publication Date Title
Gardner What we have learned about addiction from animal models of drug self-administration
Iwamoto et al. Multiple opioid receptors
O’Brien Drug addiction and drug abuse
Gamberino et al. Neurobiology of tobacco smoking and other addictive disorders
Olive Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction
O’Brien Drug addiction
JPS63303966A (ja) パーキンソン疾患治療用薬剤
US20050148673A1 (en) Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
JP2009526833A (ja) 代替療法を最適化し、薬局方を全体的な嗜癖の治療に拡大適用するための新規な薬剤組成物
Huang et al. D1 dopamine receptors
Filip et al. Implication of the nucleus accumbens shell, but not core, in the acute and sensitizing effects of cocaine in rats
Gu et al. Mechanisms of eosinophil major basic protein-induced hyperexcitability of vagal pulmonary chemosensitive neurons
CN103877096B (zh) 盐酸氯卡色林在制备抑制阿片类物质成瘾和戒断反应的药物中的应用
Wennemer et al. Fluoxetine blocks expression but not development of sensitization to morphine-induced oral stereotypy in rats
JP2008519016A (ja) 新規な医薬品組成物および様々な形の薬物嗜癖を制御するためのそれらの使用
CN101305997B (zh) 一种治疗阿片类物质戒断后神经功能紊乱的药物
Deslandes et al. Drug dependence: neuropharmacology and management
Basak et al. An Insight into the Cellular Mechanisms of Addiction to Psychostimulants
CN104666305B (zh) 一种高选择性5‑羟色胺5‑ht2c受体激动剂way163909的用途
Kufahl et al. Potential use of antidepressants as therapies for drug use disorders
Gore Behavioral characterization of substituted amphetamines and their synthetic cathinone analogues in the Rusty crayfish (Orconectes rusticus)
Ritz Molecular mechanisms of addictive substances
KR20050032590A (ko) 알코올 및/또는 담배 소비 감소를 위한 의약 및 방법
Simmons et al. Behavioral Profiles and Underlying
Fung Studies of a novel analgesic identified by establishing a structure-activity relationship for the analgesic prototype, isovaline

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100219

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120321